BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: da Silva RP, Gonçalves JIB, Zanin RF, Schuch FB, de Souza APD. Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:657363. [PMID: 34054820 DOI: 10.3389/fimmu.2021.657363] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Smith N, Possémé C, Bondet V, Sugrue J, Townsend L, Charbit B, Rouilly V, Saint-andré V, Dott T, Pozo AR, Yatim N, Schwartz O, Cervantes-gonzalez M, Ghosn J, Bastard P, Casanova JL, Szwebel T, Terrier B, Conlon N, O’farrelly C, Cheallaigh CN, Bourke NM, Duffy D. Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. Nat Commun 2022;13:7254. [DOI: 10.1038/s41467-022-34895-1] [Reference Citation Analysis]
2 Butler-Laporte G, Gonzalez-Kozlova E, Su CY, Zhou S, Nakanishi T, Brunet-Ratnasingham E, Morrison D, Laurent L, Afilalo J, Afilalo M, Henry D, Chen Y, Carrasco-Zanini J, Farjoun Y, Pietzner M, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk N, Moussa Y, DeLuca C, Duggan N, Schurr E, Brassard N, Durand M, Del Valle DM, Thompson R, Cedillo MA, Schadt E, Nie K, Simons NW, Mouskas K, Zaki N, Patel M, Xie H, Harris J, Marvin R, Cheng E, Tuballes K, Argueta K, Scott I, Greenwood CMT, Paterson C, Hinterberg M, Langenberg C, Forgetta V, Mooser V, Marron T, Beckmann N, Kenigsberg E, Charney AW, Kim-Schulze S, Merad M, Kaufmann DE, Gnjatic S, Richards JB; Mount Sinai COVID-19 Biobank Team. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics 2022;19:34. [PMID: 36171541 DOI: 10.1186/s12014-022-09371-z] [Reference Citation Analysis]
3 Bencze D, Fekete T, Pázmándi K. Correlation between Type I Interferon Associated Factors and COVID-19 Severity. Int J Mol Sci 2022;23:10968. [PMID: 36142877 DOI: 10.3390/ijms231810968] [Reference Citation Analysis]
4 Córdova-Dávalos LE, Hernández-Mercado A, Barrón-García CB, Rojas-Martínez A, Jiménez M, Salinas E, Cervantes-García D. Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children. Virus Genes 2022. [PMID: 36085536 DOI: 10.1007/s11262-022-01932-6] [Reference Citation Analysis]
5 Fricke-galindo I, Martínez-morales A, Chávez-galán L, Ocaña-guzmán R, Buendía-roldán I, Pérez-rubio G, Hernández-zenteno RDJ, Verónica-aguilar A, Alarcón-dionet A, Aguilar-duran H, Gutiérrez-pérez IA, Zaragoza-garcía O, Alanis-ponce J, Camarena A, Bautista-becerril B, Nava-quiroz KJ, Mejía M, Guzmán-guzmán IP, Falfán-valencia R. IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19. Front Immunol 2022;13:949413. [DOI: 10.3389/fimmu.2022.949413] [Reference Citation Analysis]
6 Cassão G, Antunes KH, Gonçalvez JIB, Santos LD, Abbadi BL, Bizarro CV, Machado P, Basso LA, Pasquali C, Stein RT, Souza APDD. OM-85 reduces SARS-COV-2 viral RNA expression in nasopharyngeal cells from COVID-19 patients.. [DOI: 10.1101/2022.07.29.502045] [Reference Citation Analysis]
7 Khorramdelazad H, Kazemi MH, Azimi M, Aghamajidi A, Mehrabadi AZ, Shahba F, Aghamohammadi N, Falak R, Faraji F, Jafari R. Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019. Eur J Pharmacol 2022;927:175051. [PMID: 35618037 DOI: 10.1016/j.ejphar.2022.175051] [Reference Citation Analysis]
8 Yeh YC, Doan LH, Huang ZY, Chu LW, Shi TH, Lee YR, Wu CT, Lin CH, Chiang ST, Liu HK, Chuang TH, Ping YH, Liu HS, Huang CF. Honeysuckle (Lonicera japonica) and Huangqi (Astragalus membranaceus) Suppress SARS-CoV-2 Entry and COVID-19 Related Cytokine Storm in Vitro. Front Pharmacol 2021;12:765553. [PMID: 35401158 DOI: 10.3389/fphar.2021.765553] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Georgakopoulou VE, Lembessis P, Skarlis C, Gkoufa A, Sipsas NV, Mavragani CP. Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes. Front Med 2022;9:850472. [DOI: 10.3389/fmed.2022.850472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dharmaratne M, Kulkarni AS, Fard AT, Mar JC. scShapes: A statistical framework for identifying distribution shapes in single-cell RNA-sequencing data.. [DOI: 10.1101/2022.02.13.480299] [Reference Citation Analysis]
11 Nagaoka K, Kawasuji H, Murai Y, Kaneda M, Ueno A, Miyajima Y, Fukui Y, Morinaga Y, Yamamoto Y. Circulating Type I Interferon Levels in the Early Phase of COVID-19 Are Associated With the Development of Respiratory Failure. Front Immunol 2022;13:844304. [DOI: 10.3389/fimmu.2022.844304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Alidjinou EK, Hirabidian M, Rabat A, Ouafi M, Nekoua MP, Sane F, Poissy J, Hober D; The Lille COVID Research Network (LICORNE). Low Serum Levels of Interferon Alpha in COVID-19 Patients Are Associated with Older Age. JCM 2022;11:961. [DOI: 10.3390/jcm11040961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gerhardt T, Haghikia A, Stapmanns P, Leistner DM. Immune Mechanisms of Plaque Instability. Front Cardiovasc Med 2022;8. [DOI: 10.3389/fcvm.2021.797046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]